Format

Send to

Choose Destination
Cancer Epidemiol Biomarkers Prev. 2016 Nov;25(11):1449-1455. Epub 2016 Aug 9.

Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps.

Author information

1
Division of Cancer Control and Population Studies, National Cancer Institute, Bethesda, Maryland. marcusp@mail.nih.gov.
2
Department of Applied Health Research, University College London, London, England, United Kingdom.
3
Division of Environmental Health Sciences, University of Minnesota School of Public Health, Minneapolis, Minnesota.
4
Division of Cancer Control and Population Studies, National Cancer Institute, Bethesda, Maryland.
5
Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, California.
6
Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania.
7
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
8
Department of Public Health Sciences, University of California, Davis, Sacramento, California.
9
Department of Public Health and Primary Care and Department of Oncology, University of Cambridge, Cambridge, England, United Kingdom.
10
Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland.
11
Carbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.
12
Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
13
Department of Clinical Science, UT Southwestern Medical Center, Dallas, Texas.
14
Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York.
15
Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, Georgia.

Abstract

Precision medicine, an emerging approach for disease treatment that takes into account individual variability in genes, environment, and lifestyle, is under consideration for preventive interventions, including cancer screening. On September 29, 2015, the National Cancer Institute sponsored a symposium entitled "Precision Cancer Screening in the General Population: Evidence, Epidemiology, and Next Steps". The goal was two-fold: to share current information on the evidence, practices, and challenges surrounding precision screening for breast, cervical, colorectal, lung, and prostate cancers, and to allow for in-depth discussion among experts in relevant fields regarding how epidemiology and other population sciences can be used to generate evidence to inform precision screening strategies. Attendees concluded that the strength of evidence for efficacy and effectiveness of precision strategies varies by cancer site, that no one research strategy or methodology would be able or appropriate to address the many knowledge gaps in precision screening, and that issues surrounding implementation must be researched as well. Additional discussion needs to occur to identify the high priority research areas in precision cancer screening for pertinent organs and to gather the necessary evidence to determine whether further implementation of precision cancer screening strategies in the general population would be feasible and beneficial. Cancer Epidemiol Biomarkers Prev; 25(11); 1449-55.

PMID:
27507769
PMCID:
PMC5165650
DOI:
10.1158/1055-9965.EPI-16-0555
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center